Claims
- 1. A compound of the formula ##STR16## wherein R is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, Z' is selected from the group consisting of hydrogen and alkyl of 1 to 10 carbon atoms, n is 0, 1 or 2 and A is selected from the group consisting of hydrogen, --COOR.sub.2 and --COR.sub.1, R.sub.2 is linear alkyl of 1 to 15 carbon atoms and R.sub.1 is selected from the group consisting of alkyl of 1 to 18 carbon atoms optionally substituted with a double bond or --0-- and polymethoxyphenyl.
- 2. A 1-benzyl-4-piperidyloxy-alkanols of the formula ##STR17## wherein R is selected from the group consisting of hydrogen and alkly of 1 to 4 carbon atoms, Z' is selected from the group consisting of hydrogen and alkyl of 1 to 10 carbon atoms, n is 0, 1 or 2 and A is selected from the group consisting of hydrogen, --COOR.sub.2 and --COR.sub.1, R.sub.2 is linear alkyl of 1 to 15 carbon atoms and R.sub.1 is selected from the group consisting of alkyl of 1 to 18 carbon atoms optionally substituted with a double bond or --0-- and polymethoxyphenyl.
- 3. A process for the preparation of a compound of claim 1 which comprises reacting a cyclic acetal of 1-benzyl-4-piperidone of the formula ##STR18## with lithium aluminum hydride in the presence of a Lewis acid or an organo magnesium compound of the formula
- Z--Mg--Hal
- wherein Hal is chlorine, bromine or iodine and Z is alkyl of 1 to 10 carbon atoms to obtain the corresponding compound of the formula ##STR19## wherein R, Z' and n have the above definition, reacting the latter with hydrogen in the presence of a palladium catalyst to form the corresponding compound of claim 1.
- 4. A neuroleptic composition comprising an effective amount of a compound of the formula ##STR20## wherein X is selected from the group consisting of hydrogen, chlorine, --CF.sub.3, --OCH.sub.3 and SCH.sub.3, B and R are individually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, Z' is selected from the group consisting of hydrogen and alkyl of 1 to 10 carbon atoms, p is 0 or 1, n is 0, 1 or 2 and A is selected from the group consisting of hydrogen, --COOR.sub.2 and --COR.sub.1, R.sub.2 is linear alkyl of 1 to 15 carbon atoms and R.sub.1 is selected from the group consisting of alkyl of 1 to 18 carbon atoms optionally containing a double bond or --0-- and a polymethoxyphenyl and their non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier.
- 5. A method of treating maniac excitation in warm-blooded animals which comprises administering to warm-blooded animals an effective amount of a compound of the formula ##STR21## wherein X is selected from the group consisting of hydrogen, chlorine, --CF.sub.3, --OCH.sub.3 and SCH.sub.3, B and R are individually selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, Z' is selected from the group consisting of hydrogen and alkyl of 1 to 10 carbon atoms, p is 0 or 1, n is 0, 1 or 2 and A is selected from the group consisting of hydrogen, --COOR.sub.2 and --COR.sub.1, R.sub.2 is linear alkyl of 1 to 15 carbon atoms and R.sub.1 is selected from the group consisting of alkyl of 1 to 18 carbon atoms optionally containing a double bond or --0-- and a polymethoxyphenyl and their non-toxic, pharmaceutically acceptable acid addition salts.
- 6. The method of claim 5 wherein the compound is selected from the group consisting of 10-[3-(4-.beta.-hydroxyethoxy-piperidino)-propyl]-2-trifluoromethyl-phenothiazine and its nontoxic, pharmaceutically acceptable acid addition salts.
- 7. The method of claim 5 wherein the compound is selected from the group consisting of 10-{3-[4-(2-hexadecanoyloxyethoxy)-piperidino]-propyl}-2-trifluoromethyl-phenothiazine and its nontoxic, pharmaceutically acceptable acid addition salts.
- 8. The method of claim 5 wherein the compound is selected from the group consisting of 10-[2-methyl-3-(4-.beta.-hydroxyethoxypiperidino)-propyl]-2-methoxy-phenothiazine and its nontoxic, pharmaceutically acceptable acid addition salts.
Priority Claims (4)
Number |
Date |
Country |
Kind |
72.39673 |
Nov 1972 |
FR |
|
73.31698 |
Sep 1973 |
FR |
|
71.17509 |
May 1971 |
FR |
|
71.17510 |
May 1971 |
FR |
|
PRIOR APPLICATION
This application is a division of our copending, commonly assigned application Ser. No. 479,995 filed Oct. 19, 1973, now U.S. Pat. No. 3,891,636 granted June 24, 1975, which in turn is a continuation-in-part of our copending commonly assigned U.S. patent application Ser. No. 252,461 filed May 11, 1972, now abandoned.
US Referenced Citations (5)
Non-Patent Literature Citations (1)
Entry |
Schenker-Herbst, Progress in Drug Research, vol. 5, frontispage and pp. 269, 304 to 307 and 419 to 426, Birkhauser Verlag Basel and Stuttgart (1963). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
497995 |
Oct 1973 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
252461 |
May 1972 |
|